Isis Pharmaceuticals (ISIS) 8.54 0.21

Isis Pharmaceuticals, Inc.
(ISIS) 8.54 0.21

Last Trade:	8.54	Day Range:	8.39 - 8.625
Trade Time:	12:02PM	52wk Range:	6.25 - 9.61
Prev. Close:	8.33	Market Cap:	851.69M
Open:	8.43	Div Yield:	0
Volume:	170199	PE:
EPS:	-0.79

The Latest On ISIS

ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein 1/5/12 8:07am

Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy 1/4/12 8:31am

Isis Initiates Phase 1 Clinical Trial of ISIS-FGFR4Rx a Peripherally Acting Drug to Treat Obesity 12/20/11 8:02am

Isis Updates KYNAMRO Submission Timeline 12/15/11 8:02am

Isis Reports Positive Phase 1 Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without 12/12/11 11:00am

Isis Reports Positive Phase 1 Data Demonstrating ISIS-APOCIIIRx Produces Significant Reductions in apoC-III Protein Levels 12/6/11 8:02am

Piper Jaffray Reiterates Neutral, $10 Target on ISIS Pharmaceuticals 11/30/11 10:17am

United States Patent and Trademark Office Upholds Key Santaris Pharma A/S LNA Patents in Two Re-Examination Cases Brought by Isis Pharmaceuticals 11/30/11 7:15am

UPDATE: Isis to Receive Up to $14M from Pfizer for Its Acquisition of Excaliard Pharmaceuticals 11/22/11 7:31am

End-of-Day Market Summary for November 7, 2011 11/7/11 4:16pm

Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes 11/2/11 6:04am

Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma 9/23/11 7:01am

ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein 1/5/12

Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy 1/4/12

Isis Initiates Phase 1 Clinical Trial of ISIS-FGFR4Rx a Peripherally Acting Drug to Treat Obesity 12/20/11

Isis Updates KYNAMRO Submission Timeline 12/15/11

Isis Reports Positive Phase 1 Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without 12/12/11

Isis Reports Positive Phase 1 Data Demonstrating ISIS-APOCIIIRx Produces Significant Reductions in apoC-III Protein Levels 12/6/11

Piper Jaffray Reiterates Neutral, $10 Target on ISIS Pharmaceuticals 11/30/11

United States Patent and Trademark Office Upholds Key Santaris Pharma A/S LNA Patents in Two Re-Examination Cases Brought by Isis Pharmaceuticals 11/30/11

UPDATE: Isis to Receive Up to $14M from Pfizer for Its Acquisition of Excaliard Pharmaceuticals 11/22/11

End-of-Day Market Summary for November 7, 2011 11/7/11

Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes 11/2/11

Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma 9/23/11

Engulfed 09-06-2011 9/7/11

Calls Purchased on Isis Pharmaceuticals (ISIS) 4/7/11

Upside Purchased on Isis Pharma (ISIS) 9/29/10

Top 5 Small-Cap NASDAQ Stocks In The Healthcare Sector With The Highest Cash (ONXX, ISIS, MYGN, CBST, VPHM) 6/7/10

Cantor Recommends Isis Pharma And Star Bulk Carriers (ISIS, SBLK) 5/21/10

Benzinga’s Top Pre-Market Losers (ISIS, OMNI, NLST, ATPG, TRMA) 5/3/10

Benzinga’s Volume Movers (ISIS, KMGB, CLNE, SYNA, GIVN) 3/31/10

Cantor Fitzgerald Reiterates Isis Pharmaceuticals (ISIS) Buy Rating 3/8/10

Benzinga’s Top Pre-Market Losers (ISIS, ULTI, TUES, MU, EXBD) 2/16/10

Stocks That Created New 52-Week Lows (AFCB, BFSB, FTEK, ICOPW, ISIS) 2/11/10

Benzinga’s Top Pre-Market Losers (ISIS, ULTI, TUES, MU, EXBD) 2/11/10

Benzinga’s Top Losers (ISIS, ULTI, PKY, KAZ, DF) 2/10/10

Piper Jaffray Reiterates Neutral, $10 Target on ISIS Pharmaceuticals 11/30/11

End-of-Day Market Summary for November 7, 2011 11/7/11

Piper Jaffray Updates On ISIS Following Shareholders Meeting 6/17/11

Citi Reports Uneventful 4Q For Isis Pharmaceuticals 3/1/11

Piper Jaffray Maintains $10 PT, Neutral Rating On ISIS 3/1/11

Piper Jaffray Sees 25% Upside In ISIS Pharmaceuticals (ISIS) 9/2/10

Piper Jaffray Downgrading Shares of ISIS Pharmaceuticals (ISIS) 8/5/10

Piper Jaffray Reiterates Overweight Rating On ISIS Pharmaceuticals (ISIS) 6/21/10

Piper Jaffray Maintains Overweight Rating For ISIS 5/20/10

ISIS’ Mipomersen Continues To Be The Main Driver 4/15/10

Barron’s; Amegen And Spectrum Top Pharma Picks (AMGN, ISIS, SPPI, GENZ) 4/5/10

ISIS Collaboration With GlaxoSmithKline Not Favorable 3/31/10

Trade ISIS
NOW!

Partner Headlines

Alnylam Delivers In-Line Numbers - Analyst Blog 2/13/12

The Zacks Analyst Blog Highlights: General Motors, Toyota Motor, Ford Motor, Biogen Idec and Isis Pharmaceuticals - Press Releases 1/13/12

Isis-Biogen Team Up - Analyst Blog 1/12/12

Biogen joins Isis on spinal drug 1/4/12

Alnylam States Preclinical Data - Analyst Blog 12/30/11

Still Bullish on Alnylam - Analyst Blog 12/7/11

Pfizer Nets Excaliard Pharma - Analyst Blog 12/5/11

Pfizer Signs Another Deal - Analyst Blog 11/23/11

Pfizer 11/22/11

Wider Loss at Isis Pharma - Analyst Blog 11/10/11

Rewards Balance Risk at Alnylam - Analyst Blog 8/30/11

Isis Pharma Narrows Loss - Analyst Blog 8/10/11

Press Releases

Isis Pharmaceuticals to Present at Leerink Swann's 2012 Global Healthcare Conference 2/8/12 Newswire Story

Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation 1/5/12 Newswire Story

ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein 1/5/12 Newswire Story

Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy 1/4/12 Business Wire Story

Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation 12/20/11 Newswire Story

Isis Initiates Phase 1 Clinical Trial of ISIS-FGFR4Rx a Peripherally Acting Drug to Treat Obesity 12/20/11 Newswire Story

Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy 12/19/11 Newswire Story

Isis Updates KYNAMRO Submission Timeline 12/15/11 Newswire Story

Isis Adds Three New Drugs to Its Development Pipeline 12/14/11 Newswire Story

GreenVolts Unveils Industry's First and Only Fully Integrated Solar System 12/14/11 Business Wire Story

Isis Reports Positive Phase 1 Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding 12/12/11 Newswire Story

Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Additions to its Development Pipeline 12/8/11 Newswire Story

Get the latest ISIS stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Isis Pharmaceuticals, Inc. stock price.

Isis Pharmaceuticals, Inc. by YCharts